AN2 Therapeutics annual operating cash flow
2021
2022
2023
2024
2025
AN2 Therapeutics Operating Cash Flow Growth & History (ANTX)
AN2 Therapeutics's operating cash flow was −$29.8M for fiscal 2025.
View full AN2 Therapeutics company overviewAN2 Therapeutics annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$29.8M | $19.4M | — |
| 2024 | 2024-12-31 | −$49.3M | $4.0M | — |
| 2023 | 2023-12-31 | −$53.3M | −$19.8M | — |
| 2022 | 2022-12-31 | −$33.5M | −$13.0M | — |
| 2021 | 2021-12-31 | −$20.5M | — | — |
AN2 Therapeutics quarterly operating cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$7.0M | $601,000 | — |
| Q1 2026 | 2026-03-31 | −$12.1M | −$1.4M | — |
| Q4 2025 | 2025-12-31 | −$5.2M | $37,000 | — |
| Q3 2025 | 2025-09-30 | −$6.4M | $5.6M | — |
| Q2 2025 | 2025-06-30 | −$7.6M | $6.8M | — |
| Q1 2025 | 2025-03-31 | −$10.6M | $7.0M | — |
| Q4 2024 | 2024-12-31 | −$5.3M | $11.8M | — |
| Q3 2024 | 2024-09-30 | −$12.0M | −$207,000 | — |
| Q2 2024 | 2024-06-30 | −$14.4M | −$1.6M | — |
| Q1 2024 | 2024-03-31 | −$17.6M | −$6.0M | — |
| Q4 2023 | 2023-12-31 | −$17.1M | −$9.4M | — |
| Q3 2023 | 2023-09-30 | −$11.8M | −$2.3M | — |
| Q2 2023 | 2023-06-30 | −$12.8M | −$3.2M | — |
| Q1 2023 | 2023-03-31 | −$11.6M | −$4.9M | — |
| Q4 2022 | 2022-12-31 | −$7.6M | $1.4M | — |
| Q3 2022 | 2022-09-30 | −$9.5M | −$4.8M | — |
| Q2 2022 | 2022-06-30 | −$9.6M | −$4.3M | — |
| Q1 2022 | 2022-03-31 | −$6.7M | −$5.2M | — |
| Q4 2021 | 2021-12-31 | −$9.0M | — | — |
| Q3 2021 | 2021-09-30 | −$4.7M | — | — |
| Q2 2021 | 2021-06-30 | −$5.3M | — | — |
| Q1 2021 | 2021-03-31 | −$1.5M | — | — |
AN2 Therapeutics operating cash flow trends
Between the periods ended 2021-12-31 and 2025-12-31, AN2 Therapeutics's operating cash flow decreased from −$20.5M to −$29.8M, a change of −$9.3M. The latest reported quarter, Q2 2026, shows −$7.0M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AN2 Therapeutics source filings ↗